Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Inke S.A: APIs manufacturing plant.

    Virtual Booth

    Contact Supplier

    xyz-pharma-2025-04-21

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-04-28

    Virtual Booth

    An Enquiry

    Menu

    Annamycin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Moleculin's Annamycin Shows Promise in Pancreatic Cancer
    Moleculin's Annamycin Shows Promise in Pancreatic Cancer

    29 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/29/3070231/0/en/Moleculin-Announces-New-Pre-Clinical-Data-for-Annamycin-Demonstrating-Market-Expansion-Potential-Including-Treatment-for-Pancreatic-Cancer.html

    GLOBENEWSWIRE
    29 Apr 2025
    Share Share
    Moleculin Enhances Global Exclusivity with More Annamycin Patents
    Moleculin Enhances Global Exclusivity with More Annamycin Patents

    06 Mar 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/moleculin-announces-additional-annamycin-patent-allowances-to-enhance-global-exclusivity-302393600.html

    PR NEWSWIRE
    06 Mar 2025
    Share Share
    Moleculin Gets EU Nod To Recruit For MIRACLE Ph3 AML Trial
    Moleculin Gets EU Nod To Recruit For MIRACLE Ph3 AML Trial

    11 Feb 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/moleculin-receives-first-country-approval-in-europe-to-begin-recruiting-for-the-miracle-phase-3-rr-acute-myeloid-leukemia-aml-pivotal-trial-302372939.html

    PR NEWSWIRE
    11 Feb 2025
    Share Share
    Moleculin's Annamycin Phase 2 AML Data Surpasses Top Competitors
    Moleculin's Annamycin Phase 2 AML Data Surpasses Top Competitors

    08 Jan 2025

    // #N/A

    https://www.prnewswire.com/news-releases/moleculin-highlights-development-progress-of-annamycin-phase-2-data-outperforms-billion-dollar-assets-in-aml-phase-3-data-readouts-in-2025--2026-302345069.html

    #N/A
    08 Jan 2025
    Share Share
    Moleculin Reports Q2 2024 Results And Provides Corporate Update
    Moleculin Reports Q2 2024 Results And Provides Corporate Update

    14 Aug 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/moleculin-reports-second-quarter-2024-financial-results-and-provides-corporate-update-302221619.html

    PR NEWSWIRE
    14 Aug 2024
    Share Share
    Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML
    Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML

    10 Jul 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/moleculin-completes-end-of-phase-2-meeting-with-fda-for-annamycin-in-aml-302192692.html

    PR NEWSWIRE
    10 Jul 2024
    Share Share